Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of NxClinical™,
the leading software solutions for visualization, interpretation
and reporting of genomic data, hosted the third day of 2022
Symposium, the Company’s premiere event showcasing OGM research
applications across key clinical areas of constitutional genetic
disease, hematologic malignancies, solid tumors and OGM combined
with next-generation sequencing (NGS).
Seven presentations from leading researchers across
North America and Europe showcased the utility of OGM for analysis
of solid tumors at 2022 Symposium. Seven presentations
from experts across North America and Europe shared how OGM can
characterize genetic aberrations in a wide variety of cancers, such
as pediatric brain tumors, pulmonary mesothelioma and many others.
Their findings consistently demonstrated high concordance of OGM
results for structural variants (SVs) identified by traditional
cytogenetic and molecular methods. These researchers also shared
novel applications of OGM that generated insights may guide
clinical oncology care.
Evidence has demonstrated that OGM workflows can be
scalable and can address an unmet need by providing increased
resolution and shorter turnaround times over traditional techniques
in the evaluation of solid tumors. Dr. Ravindra Kolhe,
from the Medical College of Georgia at Augusta University, showed
data from an ongoing study to characterize 100 solid tumors, where
OGM using Saphyr® demonstrated clinical utility for chromosomal
analyses, over karyotyping, fluorescence in situ hybridization, and
microarray. Based on these findings, Dr. Kolhe and his team are
working on a CLIA validation study for OGM and its subsequent
incorporation into their clinical laboratory workflow.
Two independent studies showed that pediatric brain
tumors can be rapidly characterized by OGM. Dr. Elena
Garcia Sanchez, researcher at the Hospital Infantil Universitario
Niño Jesús in Madrid, Spain presented a case study about a
13-year-old with a mediastinal mass that could not be diagnosed
using routine tests. Running pleural effusion samples using OGM on
Bionano’s Saphyr® platform, the team was able to diagnose alveolar
rhabdomyosarcoma and initiate therapy. On clinical improvement, the
mass was biopsied, and histopathology confirmed the diagnosis that
was made earlier using OGM. OGM showed concordance with traditional
testing and was shown to be a potential important tool for
detecting solid tumors that are inaccessible by routine biopsies.
While most cancers are clinically challenging, brain tumors
represent a particularly intractable group, and within pediatric
brain tumors, SVs play an important role. Dr. Miriam Bornhorst,
from Children’s National Hospital, initiated a project to determine
a more reliable approach for detection of SVs in pediatric brain
tumor samples. Dr. Bornhorst’s project demonstrated that OGM can be
an effective method for the identification of clinically relevant
SVs, some of which are not detected with other clinical testing
methods. Further clinical studies are ongoing to determine the
effect of SVs on responses to treatment and prognosis in pediatric
brain tumors.
OGM can also provide insight into the genetic variations
in a wide range of solid tumor types, including pulmonary
mesothelioma and undifferentiated small round cell
sarcomas. Mesothelioma is a slow growing cancer of the
pulmonary mesothelium that is caused by asbestos or other
particulate fibers. It is a challenging cancer to work with and to
obtain DNA from owing to the fibrotic nature of the tumor. Dr.
Matthew Couger, lead investigator at Brigham and Women’s Hospital,
has been testing Bionano’s OGM workflow for genomic
characterization of mesothelioma samples. Using OGM, Dr. Couger and
his team were able to obtain high-fidelity data to decipher the
complex chromosomal landscape. Similarly, Dr. Juan Diaz-Martin,
PhD, from the Department of Pathology-HUVR and Instituto de
Biomedicina de Sevilla presented his findings on undifferentiated
small round cell sarcomas (USRCS), a highly aggressive cancer. This
data demonstrated comprehensive characterization of genomic
aberrations using OGM that could have a significant impact on
clinical outcomes.
New applications of OGM can help solve long-standing
challenges in genetic discovery. Inherited forms of breast
cancer have been well-established in the medical literature.
However, despite routine evaluation, the causative variant cannot
be identified in some high-risk breast cancer cases. Dr. Tuomo
Mantere, from University of Oulu, Finland, presented data using OGM
to identify new SVs in breast cancer genes in these high-risk
families. In a separate example, Dr. Gopalrao Velagaleti, from
University of Texas Health, discussed work using OGM to
authenticate and characterize cell lines for research laboratories.
Working with contaminated and unauthenticated cell lines impacts
research and can have a significant cost in research dollars. Dr.
Velagaleti concluded that OGM’s high resolution and short
turnaround times can make it more cost-effective for authenticating
and characterizing cell lines as compared to traditional
methods.
“Today’s sessions demonstrate emerging applications of OGM
across a wide variety of solid tumor types,” remarked Alka Chaubey,
PhD, FACMG, Chief Medical Officer of Bionano. “We are already
seeing how the ability of OGM to identify structural variants in
cancer can solve unmet needs for solid tumor interrogation, in some
cases immediately impacting clinical decision-making.”
“We are very impressed with the data our oncology research
clients shared today, including its breadth and relevance to cancer
care decisions,” commented Erik Holmlin, PhD, President and
Chief Executive Officer of Bionano. “We believe the opportunities
for OGM to consolidate laboratory workflows, reduce time to
results, and positively impact human health are growing in an
exciting way.”
Don’t miss Symposium, register now! Symposium
registration is open to all and there is no charge for attending
this event. Register today at
https://www.labroots.com/ms/virtual-event/bngo2022.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the ability and
utility of OGM to be an effective method for the identification of
clinically relevant SVs, to solve unmet needs or have a significant
impact on clinical outcomes, to authenticate and characterize cell
lines and to consolidate laboratory workflows, reduce time to
results and positively impact human health. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes
in the competitive landscape, including the introduction of
competitive technologies or improvements in existing technologies;
failure of future study results to support those demonstrated
during the presentations referenced in this press release; changes
in our strategic and commercial plans; our ability to obtain
sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of OGM or our technologies; and the risks and uncertainties
associated with our business and financial condition in general,
including the risks and uncertainties described in our filings with
the Securities and Exchange Commission, including, without
limitation, our Annual Report on Form 10-K for the year ended
December 31, 2020 and in other filings subsequently made by us with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024